PARIS, Aug. 15, 2023 (WORLD NEWSWIRE) — Curium, a world leader in nuclear medication, revealed today the positive outcomes of the multi-center, open-label, Phase 2 SOLAR research study of Copper Cu 64 PSMA I&T in clients with histologically-proven metastatic prostate cancer. The research study has actually fulfilled the co-primary endpoints of region-level appropriate localization rate and patient-level appropriate detection rate. The function of this research study was to assess the safety, biodistribution, and image quality of Copper Cu 64 PSMA I&T to discover metastatic prostate cancer utilizing PET/CT imaging. The SOLAR Phase 2 research study was carried out in the U.S. and consisted of a group of 26 clients with metastatic prostate cancer.
Michael Patterson, CEO – North America at Curium, commented, “The milestone announced today demonstrates Curium’s global commitment to driving innovations in prostate cancer diagnosis and treatment, and is extremely encouraging for prostate cancer patients. Our proven ability to reliably manufacture and distribute Cu-64 diagnostic agents throughout the U.S. means that we are well positioned for the upcoming Phase 3 trials to ultimately improve the lives of patients.”
Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium, commented, “We are very pleased to report that our Copper Cu 64 PSMA I&T product for PET/CT imaging in the detection of recurrent prostate cancer has met the co-primary endpoints. Consistent with our mission to redefine the experience of cancer through our trusted legacy in nuclear medicine, we are encouraged by the readouts of the SOLAR Phase 2 clinical trial. Our goal is to accelerate the Copper Cu 64 PSMA I&T Phase 3 clinical development and move forward with pivotal Phase 3 clinical trials in biochemical recurrence and initial staging setting in metastatic prostate cancer in early 2024.”
Prostate cancer is the 2nd most typical cancer after skin cancer amongst males in the United States. There will be an approximated 288,000 brand-new cases of prostate cancer in 2023.
For more info about the SOLAR trial: https://www.curiumpharma.com/resources/current-clinical-trials/solar-clinical-trial/
To contact Curium’s SOLAR scientific trial group: [email protected]
About Curium
Curium is a world leader in nuclear medication. We establish, make, and disperse first-rate radiopharmaceutical items to help clients around the world. Our tested heritage integrated with a pioneering method are the trademarks to provide development, quality, and unequaled service. With making centers throughout Europe and the United States, Curium provides SPECT, animal and healing radiopharmaceutical options for lethal illness to over 14 million clients every year. The name ‘Curium’ honors the tradition of pioneering radioactive products scientists Marie and Pierre Curie, after whom the radioactive component curium was called and stresses our concentrate on nuclear medication. To learn more, see www.curiumpharma.com
For more info:
Ross Bethell
VP, Head of Global Communications
[email protected]
